Harze und Harzs?uren

Ohne Zusammenfassung     

Synthesis of novel 1,3,4‐oxadiazinane‐2‐thiones derived from (1R,2S‐ephedrine, (1S,2S)‐pseudoephedrine and (1R,2S)‐norephedrine

A several novel 1,3,4‐oxadiazinan‐2‐thiones have been synthesized by the cyclization of β‐hydrazino‐alcohols with either carbon disulfide or 1,1′‐thiocarbonyldiimidazole (TCDI).     

Structure of the first parallel DNA quadruplex-drug complex

The first crystal structure of a drug (daunomycin) bound to a parallel-stranded intermolecular telomeric G4 quadruplex (d(TGGGGT)4) has been determined to high resolution. A planar assemblage of three daunomycin molecules stacks onto the 5' end of the G4 column, with the daunosamine substituents occupying three of the four quadruplex grooves. The surface area of the terminal G-quartet in this parallel DNA quadruplex, presently occupied by three daunomycins, is sufficiently large that it could easily accommodate other potential telomerase inhibitors such as substituted porphyrins or telomestatin.     

Dissociation of Ethoxy Methyl Carbenium Hexachioroantimonate in Methylene Chloride Solution. II. The Nature and Extent of the Dissociation

Ethoxy methyl carbenium hexachioroantimonate has been synthesized as a model compound for the propagating species in the cationic polymerization of the vinyl ethers. Its degree of dissociation in methylene chloride has been studied as a function of concentration by using the method described in Part I. A simple one two dissociation was found. The degree of dissociation, however, was less than that found with a typical initiator such as triphenyl methyl hexachioroantimonate.     

Radiation-Induced Polymerization of Ethyl Vinyl Ether in n-Pentane and Neopentane

The radiation-induced polymerization of ethyl vinyl ether was studied in n-pentane and neopentane solutions under super-dry conditions. The free ion yields of these solvents are reported to be 0.16 and 1.0, respectively. The rate of polymerization in neopentane was about twice as fast as in n-pentane. The dose-rate dependence of the rate of polymerization was found to be nearly 0.50 in both solutions. It seems clear that the free solvent ions do, indeed contribute to the initiation. Regenerative chain transfer to monomer played a more important role in n-pentane than in neopentane as revealed by the molecular weight of the polymers.     

ESR Studies of λ-Irradiated Poly[3,3-bis(chloromethyl)oxetane]

Poly[3,3-bis(chloromethyl)] oxetane in vacuo, after λ-irradiation at 77°K and room temperature, showed ESR spectra consisting of a triplet (hfs of 22.0G) and a doublet (hfs of 17.8G), respectively. The triplet ESR spectrum is attributed to the -CH₂-C(CH₂Cl)-CH₂ -O- radical and the doublet ESR spectrum is attributed to the -CH₂-C(CH₂Cl)₂-CH-O- radical. The G values for formation of radicals are estimated to be 0.3 and 0.5 at 298 and 77°K, respectively.     

Chemical Proteomics and Phenotypic Profiling Identifies the Aryl Hydrocarbon Receptor as a Molecular Target of the Utrophin Modulator Ezutromid

Duchenne muscular dystrophy (DMD) is a fatal muscle‐wasting disease arising from mutations in the dystrophin gene. Upregulation of utrophin to compensate for the missing dystrophin offers a potential therapy independent of patient genotype. The first‐in‐class utrophin modulator ezutromid/SMT C1100 was developed from a phenotypic screen through to a Phase 2 clinical trial. Promising efficacy and evidence of target engagement was observed in DMD patients after 24 weeks of treatment, however trial endpoints were not met after 48 weeks. The objective of this study was to understand the mechanism of action of ezutromid which could explain the lack of sustained efficacy and help development of new generations of utrophin modulators. Using chemical proteomics and phenotypic profiling we show that the aryl hydrocarbon receptor (AhR) is a target of ezutromid. Several lines of evidence demonstrate that ezutromid binds AhR with an apparent K_D of 50 nm  and behaves as an AhR antagonist. Furthermore, other reported AhR antagonists also upregulate utrophin, showing that this pathway, which is currently being explored in other clinical applications including oncology and rheumatoid arthritis, could also be exploited in future DMD therapies.